Sarcopenic Obesity, Functional Outcomes, and Systemic Inflammation in Patients With Chronic Obstructive Pulmonary Disease

Pavol Joppa*, Ruzena Tkacova, Frits M. E. Franssen, Corrine Hanson, Stephen I. Rennard, Edwin K. Silverman, Merry-Lynn N. McDonald, Peter M. A. Calverley, Ruth Tal-Singer, Martijn A. Spruit, Klaus Kenn, Emiel F. M. Wouters, Erica P. A. Rutten

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Background: Both loss of muscle mass (ie, sarcopenia) and obesity adversely impact clinically important outcomes in patients with chronic obstructive pulmonary disease (COPD). Currently, there are only a few studies in patients with COPD with sarcopenia and concurrent obesity, termed sarcopenic obesity (SO). Objective: To explore the effects of SO on exercise capacity, health status, and systemic inflammation in COPD. Design/Settings/Participants: Baseline data collected from a total of 2548 participants (2000 patients with COPD, mean age (SD), 63.5 (7.1) years; and 548 controls, 54.8 (9.0) years) from ECLIPSE (Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints) study, a multicenter longitudinal observational study, were used. Measurements: All participants were divided into 4 body composition phenotypes using bioelectrical impedance analysis: (1) normal body composition, (2) obesity, (3) sarcopenia, and (4) SO. In patients with COPD, the 6-minute walking distance, disease-specific health status, and plasma inflammatory markers were compared among the respective body composition groups. Results: Patients with COPD were 3 times more likely to present with SO compared with controls without COPD (odds ratio [OR] 3.3, 95% confidence interval [CI] 2.0-5.4, P
Original languageEnglish
Pages (from-to)712-718
JournalJournal of the American Medical Directors Association
Volume17
Issue number8
DOIs
Publication statusPublished - 1 Aug 2016

Keywords

  • Body composition
  • sarcopenic obesity
  • chronic obstructive pulmonary disease
  • 6-minute walking distance
  • fibrinogen
  • systemic inflammation

Cite this